Mirabella Financial Services LLP Invests $2.54 Million in argenx SE (NASDAQ:ARGX)

Mirabella Financial Services LLP purchased a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,131 shares of the company's stock, valued at approximately $2,539,000.

A number of other hedge funds also recently modified their holdings of the business. FMR LLC increased its stake in argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Capital World Investors boosted its holdings in shares of argenx by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after buying an additional 86,687 shares during the period. Clearbridge Investments LLC increased its position in shares of argenx by 6.8% during the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after acquiring an additional 40,330 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock worth $185,821,000 after acquiring an additional 64,183 shares during the period. Finally, Marshall Wace LLP lifted its position in argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after acquiring an additional 124,271 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Piper Sandler lifted their price target on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $720.00 target price on shares of argenx in a research report on Tuesday, April 8th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Wells Fargo & Company lifted their price target on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, Oppenheimer lifted their target price on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, argenx has an average rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Trading Up 1.7 %

NASDAQ:ARGX traded up $10.25 during mid-day trading on Friday, hitting $610.76. 130,058 shares of the company's stock were exchanged, compared to its average volume of 307,690. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The firm has a market capitalization of $37.29 billion, a P/E ratio of -694.10 and a beta of 0.60. The company has a 50 day simple moving average of $598.76 and a 200-day simple moving average of $607.23.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, analysts expect that argenx SE will post 3.13 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.